What Is MLPA? Meaning, Definition, and Principle of Multiplex Ligation-Dependent Probe Amplification (RUO)

Multiplex ligation-dependent probe amplification, usually shortened to MLPA, is a targeted molecular method used in research use only (RUO) workflows to measure the relative copy-number signal of many predefined DNA targets in a single reaction. In practical terms, it is most useful when a team already knows which loci, exons, or regions matter and needs a focused way to check whether those targets look reduced, unchanged, or increased relative to a reference set. The core idea is simple but powerful: adjacent probe binding creates a ligation-dependent specificity gate, and only successfully ligated probes move forward into a shared amplification and fragment-sizing readout.

This page is provided for research use only (RUO) discussion in B2B laboratory and project-planning contexts. It is intended to help teams understand MLPA as a targeted assay framework for predefined genomic regions, including assay selection, workflow design, QC review, and interpretation boundaries in research settings. It does not describe or promote clinical diagnosis, patient management, or treatment decision-making. Any follow-up testing strategy, orthogonal confirmation plan, or platform comparison mentioned here should be understood as part of RUO method evaluation, validation planning, or technical review within a research workflow. Final assay choice should be matched to the project objective, target definition, sample characteristics, and required evidence depth.

For early-stage project teams, the real value of understanding MLPA is not just decoding the acronym. It is knowing where the method sits in the larger assay landscape. MLPA is best viewed as a focused assay framework for predefined targets: narrower than sequencing-based discovery, but often more direct than running many separate targeted reactions when the question is copy-number oriented and panel-like. That makes it particularly relevant in research workflows where assay fit, output readability, and interpretation boundaries matter as much as the chemistry itself.

MLPA Meaning and Definition (in One Paragraph)

MLPA stands for Multiplex Ligation-Dependent Probe Amplification.

Each part of the name points to a different part of the assay logic:

• Multiplex means many predefined targets can be assessed together in one experiment.
• Ligation-dependent means signal generation depends on the successful joining of two adjacent probe halves.
• Probe means target recognition occurs through designed oligonucleotide probes rather than many independent locus-specific amplification reactions.
• Amplification means ligated probe products are then amplified with a shared primer system and measured as size-resolved fragments.

In RUO terms, MLPA is a targeted assay for relative copy-number analysis across predefined genomic regions. It is most informative when the target set is already known and the key question is whether those selected regions appear unchanged, reduced, or increased relative to a reference framework. A closely related extension, MS-MLPA, adds methylation-sensitive logic to the same overall architecture, but the classic form of MLPA is fundamentally about targeted relative dosage analysis rather than broad sequence discovery.

Figure 1. MLPA overview infographic.
A definition-first overview showing acronym meaning, adjacent probe ligation logic, and the three main output categories—ratio-style readout, QC review, and report-ready summary.

The Core Principle — Why Ligation Enables Multiplexing

The single most important concept in MLPA is that multiplexing becomes workable because target specificity is established before shared amplification begins. In other words, MLPA does use PCR, but it is not simply "many locus-specific PCR assays in one tube." The key gate is earlier: two probe halves must hybridize to immediately adjacent target sequences, and only then can they be ligated into a complete amplifiable molecule.

That design matters because it separates the assay into two distinct phases:

• 1. Target recognition through adjacent probe binding
• 2. Signal generation through amplification of only the ligated products

This architecture is what makes MLPA conceptually elegant and operationally useful. Many targets can be represented in one reaction because each probe pair carries target specificity at the hybridization-and-ligation stage, while the downstream amplification can rely on a shared primer pair. The result is a multiplexed assay that still preserves target identity through fragment length.

Step 1: DNA denaturation and adjacent probe hybridization

Purified DNA is first denatured, then incubated with MLPA probe oligonucleotides. Each target is represented by a left probe oligonucleotide and a right probe oligonucleotide. These probe halves are designed so they hybridize directly next to each other on the target sequence. An additional stuffer sequence gives the resulting ligated product a characteristic size, which later helps distinguish it from other targets during fragment analysis.

Step 2: Ligation as the specificity gate

Once both probe halves are correctly positioned, ligase can join them. This is the most important control point in the assay. MRC Holland's technical description explicitly notes that mismatches around the ligation site are not permitted, which is why this step acts as a strong specificity filter. If adjacency is wrong or the local match is poor, the ligated product will not form efficiently and that probe will not contribute a meaningful downstream signal.

Step 3: Universal amplification of ligated products

After ligation, all completed probe products share common primer sites and can be amplified in a multiplex PCR using a single universal primer pair. This is why MLPA should not be described as ordinary multiplex PCR in disguise. The target discrimination step has already happened. Universal amplification is simply the efficient readout engine for the set of ligated products that passed the earlier gate.

Step 4: Fragment sizing and peak generation

The amplified products are then separated by capillary electrophoresis, where each fragment is recognized by length. Each expected fragment corresponds to a defined probe, which means the final raw output is a peak pattern rather than a sequencing readout. That peak pattern becomes the substrate for normalization and interpretation.

For teams planning assay setup, sample submission, and reporting expectations, the next practical step is the MLPA test and assay workflow, sample requirements, and deliverables, which extends this principle into project execution.

Figure 2. Four-step MLPA mechanism.
A mechanism-focused figure showing hybridization, ligation as the specificity gate, shared amplification, and fragment sizing in a clean left-to-right workflow.

What MLPA Is Used For

MLPA is most useful when the research question is targeted, predefined, and copy-number oriented. It is not a discovery-first platform. It is a method for asking a narrower but often very practical question: "Across this set of known targets, what does the relative copy-number pattern look like?" That framing is exactly where MLPA becomes strong.

Targeted multi-exon or multi-region copy-number review

A common fit for MLPA is a project that needs to examine multiple exons or selected genomic regions at once without moving immediately to a broader sequencing design. In these cases, the assay's multiplexed structure can reduce complexity compared with running many separate targeted reactions. When the question later expands beyond a fixed target list, broader CNV sequencing services or targeted region sequencing may become more appropriate.

Follow-up after broader screening

MLPA often works well as a focused follow-up method. A broader platform may nominate regions of interest, and MLPA can then be used to examine selected targets in a compact assay framework. In that role, MLPA is not replacing a discovery platform; it is helping narrow the review to a manageable set of predefined loci.

Panel-oriented research validation

When teams are validating hypotheses around a defined group of genes or genomic intervals, MLPA can serve as a panel-like verification method. It is especially useful when relative dosage, exon coverage logic, and report simplicity matter more than full sequence context.

When MLPA is a good technical fit

MLPA is usually a good fit when:

• the project already has a stable target list,
• the main question is relative copy number rather than sequence discovery,
• multiplexed review of many predefined targets is more useful than a few isolated single-locus assays,
• and the output can be interpreted in a reference-based ratio framework.

When MLPA is not the best fit

MLPA is usually not the first choice when the project requires:

• broad exploratory profiling,
• nucleotide-resolution discovery,
• wide genomic context around candidate events,
• or integrated analysis of multiple variant classes across a much larger design space.

In those cases, methods such as gene panel sequencing or whole exome sequencing may provide a better match to the study objective.

If your next question is less "what is MLPA?" and more "how do I choose among neighboring methods?", the best continuation is the technical comparison of MLPA vs ddPCR vs qPCR vs NGS for CNV.

MLPA Outputs at a Glance (What You Get)

The most common beginner mistake is to assume that MLPA produces an answer the moment peaks appear. In practice, the output is a chain of evidence that starts with fragment peaks and becomes meaningful only after normalization, reference comparison, and quality review. MRC Holland's technical guidance states this directly: relative copy numbers are derived by comparing target and reference probe peak behavior in test samples against reference samples with known normal copy number, and advanced quality checks are used to recognize unreliable data.

1) Raw fragment peaks

The first visible output is an electropherogram-like peak pattern, where each expected fragment length corresponds to a defined probe. This is the technical starting point. It tells you whether the fragment analysis behaved as expected and whether the panel produced the anticipated set of probe signals. It does not by itself establish a target-level conclusion.

2) Normalized ratio values

The interpretive step begins after normalization. Raw peak heights are influenced by more than target abundance alone, so MLPA analysis relies on relative comparison among target probes, reference probes, test samples, and reference samples. That is why normalized ratios, not peak presence alone, carry the main interpretive weight.

3) Review-ready output tables and plots

A practical RUO handoff often includes:

• processed ratio tables,
• annotated target-level plots,
• QC comments,
• summary flags for loci requiring review,
• and a concise technical report that states what the assay supports, what remains uncertain, and what may need orthogonal follow-up.

Where sequence-context follow-up is needed, teams may pair MLPA findings with Sanger sequencing or multiplex PCR sequencing, depending on whether the next question is locus confirmation, nearby sequence review, or assay-specific technical clarification.

As a relative method, MLPA interpretation depends on comparison against suitable reference samples rather than raw peak presence alone; software-assisted QC review is therefore central to reliable ratio interpretation. That source-anchoring matters because it explains why a technically clean electropherogram still needs structured data review before any target-level conclusion is treated as dependable.

For a deeper discussion of study design, target-level reasoning, and how to read ratio-style outputs, continue with MLPA for CNV: study design and interpretation.

Figure 3. MLPA output and normalization workflow.
An annotated output figure showing how electropherogram peaks become normalized ratio values across target exons for review and interpretation.

Where MLPA Fits Among Alternatives

MLPA occupies a useful middle ground: more focused than sequencing-based discovery, more scalable than many separate single-target measurements, and often easier to review than a broader assay when the research question is already well defined.

Compared with small targeted assays

If the project involves only one or a few loci, a smaller targeted method may be enough. MLPA becomes more attractive when the number of predefined targets increases and the team wants one structured multiplex assay instead of many parallel single-target reactions.

Compared with array-style copy-number profiling

Array-based approaches can offer wider genomic breadth, which helps when the project is still exploratory. By contrast, MLPA is usually preferable when the target set is stable and the assay should stay focused. For broader dosage-style profiling, CGH microarray service options or SNP microarray workflows may align better with the project scope.

Compared with sequencing-based approaches

Sequencing methods provide richer sequence context and can support broader discovery, but they also increase analytical scope and often demand more extensive downstream review. When the primary need is still focused CNV-oriented interrogation of selected loci, MLPA can remain the simpler and more direct option. Once the study needs wider evidence depth, whole genome sequencing is often the more natural direction.

Decision Framework: When to Use MLPA, and When Not to

A good selection decision starts by matching the assay to the project question, not by asking which technology sounds most powerful. The table below is designed for fast screening during RUO assay planning.

This table is not meant to turn MLPA into a default choice. It is meant to stop mismatch. MLPA performs best when the project is already structured around a predefined target set and a relative copy-number question. It becomes less appropriate as the project drifts toward discovery, wide context, or sequence-first evidence.

Next Step — How to Judge Data Quality

Even at the definition stage, it is important to say clearly that MLPA data quality is not judged by peak presence alone. Reliable interpretation depends on sample quality, appropriate reference samples, stable normalization, and probe-level review. That is not a minor implementation detail; it is part of the assay's logic as a relative method. MRC Holland's workflow description emphasizes exactly this point by tying relative copy-number determination to reference comparison and advanced quality checks.

Before interpreting target-level changes, first confirm sample quality, reference-sample suitability, and normalization stability. In MLPA, a technically clean peak pattern is helpful, but ratio interpretation remains reference-dependent and probe-specific review may still be needed.

At a high level, every project team should keep the following in mind:

• Sample DNA quality matters. Problems upstream can distort hybridization, ligation, and amplification before any interpretation begins.
• Expected fragment behavior matters. Missing peaks, weak signal, or unusual size-pattern behavior should trigger technical review first.
• Reference design matters. Because MLPA is relative, unstable or unsuitable reference samples can weaken the entire interpretation chain.
• Normalization matters. Apparent changes can reflect normalization instability rather than a true target-level shift.
• Probe-level review matters. A borderline pattern in one probe should not automatically be elevated to a confident biological conclusion.
• Orthogonal follow-up may matter. If the result will influence the next stage of the research workflow, a second method may be appropriate.

As a relative method, MLPA interpretation depends on comparison against suitable reference samples rather than raw peak presence alone; software-assisted QC review is therefore central to reliable ratio interpretation. For the next layer of detail, see MLPA analysis QC, normalization, and report structure.

QC and Troubleshooting

Before interpreting target-level changes, first confirm sample quality, reference-sample suitability, and normalization stability. In MLPA, a technically clean peak pattern is helpful, but ratio interpretation remains reference-dependent and probe-specific review may still be needed.

Symptom: Many expected peaks are weak or broadly depressed

Likely cause: poor DNA input, inaccurate input quantity, incomplete denaturation, inefficient ligation, or suboptimal amplification.
Practical fix: verify DNA integrity and concentration first, then review protocol timing and temperature handling before assigning any biological meaning.

Symptom: A few probes look abnormal while neighboring targets remain stable

Likely cause: probe-specific instability, local sequence effects near the ligation site, or isolated technical noise.
Practical fix: check reproducibility, inspect the surrounding target pattern, and avoid overinterpreting a single unstable probe without supporting evidence.

Symptom: Raw peaks look acceptable, but ratios are inconsistent across samples

Likely cause: unstable reference samples, batch-level effects, or poor normalization logic.
Practical fix: re-evaluate the reference framework before revisiting target-level interpretation, because MLPA conclusions are fundamentally comparative rather than absolute.

Symptom: The assay is technically clean, but the project still lacks the needed evidence depth

Likely cause: assay-project mismatch rather than assay failure.
Practical fix: reconsider whether the question has outgrown a predefined target assay and now requires broader sequence or genome-level context.

Common Misunderstandings About MLPA

"MLPA is just another PCR assay."

Not really. PCR is part of the workflow, but MLPA's main discrimination step is adjacent probe hybridization followed by ligation. Shared amplification happens afterward.

"If the peaks are there, the answer is already clear."

Also not true. Peaks are the starting material for analysis. Interpretation depends on normalization, reference comparison, and quality review.

"MLPA replaces sequencing."

Only for the right question. MLPA is a focused assay for predefined regions; it is not a discovery platform and not a substitute for broad sequence-context analysis.

"More targets automatically make MLPA the best option."

Only when those targets are already known and the main question is still relative copy number rather than broader variant discovery.

FAQ

1) What does MLPA stand for?

MLPA stands for Multiplex Ligation-Dependent Probe Amplification, a targeted assay in which adjacent probe binding and ligation enable multiplexed downstream amplification and relative copy-number readout.

2) What does MLPA measure?

Classic MLPA measures relative copy-number signal across predefined genomic targets. A related extension, MS-MLPA, adds methylation-sensitive logic for selected research workflows.

3) Why is ligation so important in MLPA?

Because ligation acts as the specificity gate. Only correctly adjacent probe halves become joined, and only those ligated probes enter efficient shared amplification.

4) Is MLPA the same as multiplex PCR?

No. MLPA uses multiplex PCR as part of the readout, but target recognition comes from adjacent probe hybridization plus ligation, not from many separate locus-specific primer pairs.

5) What kind of output should I expect from an MLPA project?

Typical outputs include raw fragment peaks, normalized target-level ratios, QC comments, annotated plots, and a concise technical report for review.

6) When is MLPA a poor fit?

MLPA is a poor fit when the target list is not yet defined, when genome-wide context is essential, or when the project needs nucleotide-resolution evidence rather than relative copy-number review.

7) Can MLPA be combined with broader methods?

Yes. In RUO workflows, MLPA is often used as a focused follow-up or complementary method after broader screening, depending on the project objective.

8) Does a clean peak plot guarantee a reliable result?

No. A clean-looking peak pattern is useful, but interpretation still depends on reference quality, normalization stability, and probe-level review.

References:

1. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Research. 2002;30(12):e57. DOI: 10.1093/nar/gnf056
2. Nygren AOH, Ameziane N, Duarte HMB, et al. Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Research. 2005;33(14):e128. DOI: 10.1093/nar/gni127
3. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA. MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cellular Oncology. 2008;30(4):323-335. DOI: 10.3233/CLO-2008-0428
4. Coffa J, van den Berg J. Analysis of MLPA Data Using Novel Software Coffalyser.Net by MRC-Holland. In: Modern Approaches to Quality Control. 2011. DOI: 10.5772/21898
5. Benard-Slagter A, Zondervan I, de Groot K, et al. Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia. The Journal of Molecular Diagnostics. 2017;19(5):659-672. DOI: 10.1016/j.jmoldx.2017.05.004
6. Fu X, Shi Y, Ma J, et al. Advances of multiplex ligation-dependent probe amplification technology in molecular analysis workflows. BioTechniques. 2022;74:205-213. DOI: 10.2144/btn-2022-0017